BioSpace News Archive

Management will also host a conference call with investors to discuss financial results and provide a corporate update at 4:30pm Eastern Time.

The Data Safety Monitoring Board approves proceeding with enrollment of third cohort (inarigivir 100mg) of the ACHIEVE trial.

Shionogi announced it will present positive efficacy and safety results from a global Phase 3 study (L-PLUS 2) of lusutrombopag (S-888711), an investigational, once-daily, orally administered, small molecule thrombopoietin (TPO) receptor agonist, at the 2017 American Association for the Study of Liver Diseases (AASLD) Liver Meeting to be held October 20-24 in Washington, D.C.

The event will be on October 20-24, 2017, at the Washington Convention Center in Washington, D.C.

ANGLE plc, a world-leading liquid biopsy company, announces that its AGM will be held at 2:00pm on Tuesday 31 October 2017 at ANGLE plc, 10 Nugent Road, the Surrey Research Park, Guildford, GU2 7AF.

Five Prime will host a conference call and live audio webcast on Monday, November 6, 2017, at 4:30 p.m. (ET)/1:30 p.m. (PT) to discuss the company’s financial results and provide a general business update.

At this DC meeting, attendees will view the system’s 60-second non-invasive evaluation of liver stiffness with real-time ShearWave Elastography.

ThromboGenics issues a business update for the three-month period ending 30 September 2017.

Prometic today announces in vivo data from compounds PBI-4050 and PBI-4547 for the prevention and treatment of liver diseases, and associated metabolic syndrome are being presented in three poster sessions at AASLD.

Second Heart Assist, Inc. today announced the first successful implant of its Second Heart Assist, Inc. Gen. I Circulatory Support Assist device, in relevant preclinical models performed at Tufts Medical Center, in Boston, Massachusetts.